Distribution agreement brings cryo-free cell preservation to China

UK-based biotech innovator Atelerix has signed an exclusive distribution agreement with Chinese life science company MineBio to introduce its advanced, non-cryogenic cell preservation technology to the Chinese market. The deal marks Atelerix’s official entry into China and reflects its strategy to expand in Asia’s fast-growing biomedical research and cell therapy sectors.

The agreement grants MineBio sole distribution rights to Atelerix’s portfolio across China, providing local researchers and developers with easy access to a cryo-free alternative for the storage and transport of sensitive biological materials. The technology, which uses patented hydrogel encapsulation, allows cells and tissues to be preserved at room temperature for up to 14 days - avoiding the costs, complexity, and risks of traditional deep-freeze logistics.

“China represents a critical growth region for advanced therapeutic development, and we’re thrilled to be partnering with MineBio to support the demand for better biospecimen logistics,” said Alastair Carrington, CEO of Atelerix. “Our hydrogel technology brings new flexibility to cell and gene therapy workflows, and this partnership ensures our customers in China have strong local support from a trusted distributor.”

Atelerix’s solutions are compatible with a broad range of sample types - including blood, primary cells, organoids, and viruses - and do not require animal-derived or toxic additives. Designed to preserve viability and function without freezing, the technology is especially suited for live sample transport, complex in vitro modelling, and diagnostic testing.

Amy Zuo, General Manager at MineBio, added: “We’re excited to bring Atelerix’s innovations to our customers in China. Their cryo-free preservation platform supports a smoother, more sustainable supply chain for researchers working at the forefront of life sciences. This partnership strengthens our shared goal of enabling smarter, more accessible biotech workflows.”

With China conducting over a third of the world’s clinical trials and rapidly expanding its biotech infrastructure, the partnership places Atelerix in a strong position to support both research and commercial teams across the region.

More information online